Irinotecan

Generic Name: Irinotecan

Brand Names: Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₈N_₄O_₆

CAS Number: 97682-44-5

Unique Ingredient Identifier: 7673326042

Background: Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Indication: For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy

Phase 1

Completed

Conditions: Lymphomas
Tumors

First Posted Date: 2005-09-22

Last Posted Date: 2008-09-22

Lead Sponsor: University of Oklahoma

Target Recruit Count: 40

Registration Number: NCT00222443

Locations: 🇺🇸
Oklahoma University Health Sciences Center-Jimmy Everest Center, Oklahoma City, Oklahoma, United States

Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer

Phase 2

Terminated

Conditions: Rectal Cancer

Interventions: Drug: Capecitabine
Drug: Irinotecan
Procedure: EUS
Drug: Neoadjuvant Chemotherapy
Procedure: Preoperative Radiation
Procedure: Surgery
Procedure: Adjuvant Chemotherapy

First Posted Date: 2005-09-22

Last Posted Date: 2016-06-06

Lead Sponsor: Gabi Chiorean, MD

Target Recruit Count: 22

Registration Number: NCT00216086

Locations: 🇺🇸
AP&S Clinic, Terre Haute, Indiana, United States
🇺🇸
Elkhart Clinic, Elkhart, Indiana, United States
🇺🇸
Fort Wayne Oncology & Hematology, Inc, Fort Wayne, Indiana, United States

and more 6 locations

Phase I/II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer

Phase 1

Completed

Conditions: Gastric Cancer

First Posted Date: 2005-09-21

Last Posted Date: 2006-04-21

Lead Sponsor: Hokkaido Gastrointestinal Cancer Study Group

Target Recruit Count: 24

Registration Number: NCT00209638

Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial

Phase 2

Completed

Conditions: Esophageal Neoplasms

First Posted Date: 2005-09-21

Last Posted Date: 2005-10-28

Lead Sponsor: University Hospital, Rouen

Target Recruit Count: 43

Registration Number: NCT00213486

Locations: 🇫🇷
CHU de Rouen, Rouen, France

Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

First Posted Date: 2005-09-21

Last Posted Date: 2005-09-21

Lead Sponsor: Hokkaido Gastrointestinal Cancer Study Group

Target Recruit Count: 23

Registration Number: NCT00209625

Locations: 🇯🇵
Hokkaido University Hospital, Sapporo, Hokkaido, Japan

Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer

Phase 2

Suspended

Conditions: Gastric Cancer

First Posted Date: 2005-09-21

Last Posted Date: 2006-02-02

Lead Sponsor: Hokkaido Gastrointestinal Cancer Study Group

Target Recruit Count: 40

Registration Number: NCT00209664

Locations: 🇯🇵
Hokkaido University Hospital, Sapporo, Hokkaido, Japan

Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer

Phase 2

Completed

Conditions: Cancer of Stomach
Stomach Cancer
Esophageal Cancer
Esophagus Cancer

First Posted Date: 2005-09-20

Last Posted Date: 2017-12-06

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 80

Registration Number: NCT00201747

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States

Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site

Phase 3

Completed

Conditions: Neoplasms, Unknown Primary

Interventions: Drug: Gemcitabine
Drug: Etoposide
Drug: Paclitaxel
Drug: Irinotecan
Drug: Carboplatin

First Posted Date: 2005-09-19

Last Posted Date: 2013-05-03

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 198

Registration Number: NCT00193596

Locations: 🇺🇸
Tower Oncology, Beverly Hills, California, United States
🇺🇸
Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸
Jackson Oncology Associates, Jackson, Mississippi, United States

and more 28 locations